Navigation Links
Brolex C SAFE cesarean section safety device receives top scores, rated a MUST HAVE medical device for performing c/sections.
Date:12/12/2012

IRVINE, Calif., Dec. 12, 2012 /PRNewswire/ -- Brolex LLC announced today that the C SAFE cesarean section safety device was evaluated in "Reviews in Obstetrics & Gynecology." In this unsolicited review by James A. Greenberg, MD, Assistant Professor of Obstetrics, Gynecology, and Reproductive Biology at Harvard Medical School, Vice Chairman of Obstetrics and Gynecology at Brigham and Women's Hospital, and Chief of Gynecology at Faulkner Hospital, C SAFE received the highest number of perfect "5" scores in the history of "MedReviews – OB Product Reviews." This device review article is a testimony to the need, benefit, and value for hospitals to incorporate the C SAFE medical device for use in cesarean sections within their institutions. In the review article Dr. Greenberg comments "I think it is time we made newborn lacerations a "never" event and C SAFE is one tool to get us there."

The full review is available at www.csafe.us/medreviews2012.pdf and soon to be available on the MedReviews publisher's website: www.medreviews.com/issues.cfm?journal=5

The review article discusses the value of C SAFE, giving it a perfect score of 5, and goes on to state "when the costs of a laceration to a baby (including actual medical costs, malpractice costs, and the cost of the ill will generated) are added up, this device looks like one of the best bargains in health care."

Scott Berlin, MD, CEO and Founder of Brolex LLC commented, "The time is approaching that hospitals may need to explain why they didn't have C SAFE available for safer cesarean sections."  In the most recent UpToDate® Official Topic on Cesarean Delivery: Technique, Vincenzo Berghella, MD, Jefferson Medical College, lists the C SAFE device as one option for entering the uterus, as a device designed to reduce the risk of lacerating the fetus.

Mario Guralnik, PhD, COO and President of Brolex LLC explained that C SAFE is being well received by hospital risk management offices, primarily due to the medicolegal implications for a device that is designed as a SAFETY device for performing SAFER c/sections. In quoting Dr. Greenberg, "With all the wasted money we throw at the sacred altar of Patient Safety, this product actually makes sense and is worth the marginal cost." The key message is really that as c/section rates are rising around the globe, and that elective c/sections are increasingly part of the landscape, we should be acting to minimize those risks involved.   

Brolex LLC is the owner and manufacturer of the C SAFE medical device. C SAFE is a novel medical device clinically tested and designed specifically for performing safer cesarean sections by preventing lacerations to newborns.

Published literature documents there is a 1.5 - 3.0% risk of lacerations or nicks in c/sections. There is strong evidence to suggest that this rate is actually higher than reported or documented. At a documented risk of 1.5 - 3.0%, this translates to 45,000 newborns annually that experience some level of laceration injury related to c/section. For nonvertex c/sections, reports of a 6.0% risk for lacerations nearly double the number of injuries to newborns.

The C SAFE medical device reduces or eliminates laceration injury risks. Benefits of using C SAFE, as well as implementing a Risk Management and Patient Safety Initiative Program using the C SAFE device include:

  • Clinical outcomes improvement for newborns
    • Eliminate minor lacerations to acute injuries
      • Avoid short term to long term complications
  • Minimize / eliminate medical intervention costs on laceration injuries
  • Proactively address medicolegal implications
    • Lacerations do occur,
      • and have negative medical and economic consequences
    • Implications of "Best Medical Practices"
      • What happens when an available safety device is NOT used
  • Risk mitigation programs
    • Clinical Risk Mitigation
    • Legal Risk Mitigation
    • Economic Risk Mitigation

For more information, visit www.csafe.us.

CONTACT: Mario Guralnik, PhD, +1-714-660-6066


'/>"/>
SOURCE Brolex LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Distribution of C SAFE medical device for safer cesarean sections by preventing lacerations to newborns expands domestically and internationally
2. Joseph Rogers Joins SRI International as Executive Director of New Health Sciences Section in Biosciences Division
3. Kallos EMCURx Conferred Status Of "Official EMR Pediatrics Section, OMA"
4. Senate HELP Committee OKs Food and Drug Administration Safety And Innovation Act
5. PDR and the iHealth Alliance Announce New Drug Safety Certification for EHRs
6. Physician-Patient Alliance for Health & Safety: Monitoring Technology for PCA Pumps Can Prevent Adverse Events: So Why Are Hospitals Not Using It?
7. One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
8. Patient Safety Technologies Reports First Quarter 2012 Results
9. CVS Caremark Sponsored Research Finds FDA Drug Warnings Can Have Immediate Negative Impact on Medication Adherence, Even if Not Related to Safety
10. I.V. Clinical Integration Helps Deliver Safety, Efficiency And Financial Benefits; Hospira Shares Snapshot Of Results, Process
11. SurgiCount Medical Awarded Contract From HealthTrust Purchasing Group for the Safety-Sponge® System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... -- Urologix, the market leader for in-office minimally invasive ... (BPH), announces new private ownership and is operating as ... industry veteran of more than 20 years, has been ... Plymouth, Minn. The company,s two ... RF Therapy, will continue to be broadly available and ...
(Date:2/10/2016)... Feb. 10, 2016  Rich Pharmaceuticals, Inc. (OTC Markets: ... 1-for-100 reverse split of its issued and outstanding shares ... on Thursday, February 11, 2016. The Company,s common stock ... number 76303T308 and temporary ticker symbol "RCHAD". After 20 ... the ticker symbol (RCHA).  --> ...
(Date:2/10/2016)... 10, 2016  Oxis International Inc. (OTC/QB: OXIS) announced ... described as a "clinical trial triumph" after one of ... complete cancer remission. Daniel Vallera , ... Cancer Center. --> Daniel Vallera , ... Cancer Center. --> An article on ...
Breaking Medicine Technology:
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... working together to expand dental health services to the developmentally disabled in the ... Care Dental’s operations to a new facility at 71-949 Highway 111, Suite 100-B, ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand Interpreting , ... recently partnered with Heart City Health Center to improve access to ... Heart City Health Center has provided the Elkhart community with access to high ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... charity program created to assist the local community. Pledging to select a new ... nonprofit organizations in the area. Their goal is to bring community awareness to ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. ... office is now offering a variety of comprehensive procedures for facial enhancement. The ... facial volume restoration, lip enhancement and nasal reshaping. , As a result, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Intalere’s 2016 Executive Forum, ... 200 of the country’s top healthcare executives to share insights on transformational strategies ... the Forum is the provider-centric perspective, experience, expertise and strategy shared by the ...
Breaking Medicine News(10 mins):